FDA Approves First IL-17A Treatment for Teens With HS
Teenagers with hidradenitis suppurativa now have a second biologic treatment option after the FDA approved secukinumab for patients as young as 12. This matters because more than half of HS patients develop symptoms during adolescence, but treatment choices have lagged far behind adult options.